PRODUCTION OF Y90 MICROSPHERES FOR RADIATION THERAPY

用于放射治疗的 Y90 微球的生产

• 批准号: 6053190
• 负责人: YONGREN Benjamin PENG
• 金额: $ 1.45万
• 依托单位: XL SCI-TECH, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-01 至 1999-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6053190
• 关键词: biomaterial compatibility; biomaterial development /preparation; biomedical automation; biotransformation; drug design /synthesis /production; method development; microcapsule; radiation therapy; radioactive microsphere technique; radionuclides; yttrium

Low-cost production of monodispersed timed-bioresorbable microspheres containing yttrium-90 (Y-90) will have a positive impact on radiation therapy in the United States and world wide. As more emphasis is given by the medical profession to short half-life, high energy, beta emitting isotopes (such as 7-90) to minimize major side effects of radiotherapy, Y- 90 has become the isotope of choice. As more therapeutic uses are being discovered for the short half-life isotope, it is necessary that the processing time involving isotopes be kept to an absolute minimum. A fully automated production process will ensure a fresh (non-decayed) supply of microsphere, will minimize or completely eliminate personnel exposure to radiation or radioactive materials, and will utilize the source isotopes such as strontium-90 (Sr-90) most efficiently and naturally in terms of material and radioisotope life. It is the objective of this proposed program to integrate demonstrated technologies and knowledge from national laboratories and private industries with XL Sci-Tech's timed-resorbable microsphere technology. Through process innovation, continuous low cost volume production of Y-90 microspheres will be achieved. Proposed commercial application: Microspheres containing isotopes such as Y-90, P-30 are ideal for direct intratumorial injection in treatment of cancers of liver, pancreas etc., and radiation synovectomy of rheumatoid arthritis.

低成本生产单分散定时生物可吸收微球 含有钇-90（Y-90）的核燃料将对辐射产生积极影响 治疗在美国和世界各地。由于更多的强调是由 短半衰期高能量β射线 同位素（如7-90），以尽量减少放射治疗的主要副作用，Y- 90已成为首选同位素。随着越来越多的治疗用途 对于短半衰期同位素的发现， 涉及同位素的处理时间应保持在绝对最低限度。完全 自动化生产过程将确保新鲜（非腐烂）的供应， 微球，将尽量减少或完全消除人员接触 辐射或放射性物质，并将利用源同位素 例如锶-90（Sr-90），就 物质和放射性同位素寿命。这是本建议的目的 整合国家示范技术和知识的方案 实验室和私营企业与XL科技的定时吸收 微球技术通过工艺创新，持续低成本 将实现Y-90微球的批量生产。 拟议的商业应用： 含有同位素如Y-90、P-30的微球是直接用于 肿瘤内注射治疗肝癌、胰腺癌等， 和类风湿性关节炎的放射性滑膜切除术。